The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors. With the recent approval by the U.S. Food and Drug Administration (FDA) of ...

Cabometyx is approved for treating well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older. The phase 3 CABINET trial showed improved progression-free ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...

Most cancer patients receive little or no mental health support and 84% of patients with a less common cancer, neuroendocrine cancer, told us they weren’t asked how they were feeling emotionally ...

In January 2025, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors were updated to include cabozantinib as a category 1 ...

By using tiny, naturally occurring particles called extracellular vesicles (EVs), they have created a way to boost the body's immune system to fight tumors more effectively. This breakthrough ...

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. The small-molecule drug is now allowed for patients 12 years of age and ...

By Christina Hernandez Sherwood Sports partnerships are a game changer in the American Cancer Society’s fight against cancer ...

A month after that initial conversation I was diagnosed with Neuroendocrine Cancer. Worse, not only did I have a rare cancer that I’d never even heard of, but I also had a version of it (lung ...